Drugs / hEGFRvIII-CD3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04903795 | Aug 2026 → Dec 2027 expected | glioblastoma | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hEGFRvIII-CD3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04903795 ↗ |
| Modality | Protein / enzyme biologic | “Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3” NCT04903795 ↗ |
| Route | Intravenous | “continuously infused intravenously (IV)” NCT04903795 ↗ |
| Target | EGFR | “target-binding arm is directed against the hEGFRvIII epitope” NCT04903795 ↗ |